SciSparc and Clearmind Medicine's Collaboration Yields New Evidence for MEAI as a Weight Loss Drug

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, has been making significant strides in the development of treatments for obesity and metabolic syndrome through its collaboration with Clearmind Medicine Inc. This partnership merges SciSparc’s expertise in cannabinoid-based therapies with Clearmind’s innovative psychedelic-derived treatments. A recent study, led by Prof. Joseph Tam from the Hebrew University of Jerusalem, has produced promising results using Clearmind’s psychoactive molecule, MEAI, to combat obesity.

Published in ACS Pharmacology and Translational Science, the study meticulously evaluated the effects of MEAI on obesity induced by diet in mice. The findings revealed that the treatment notably reduced weight by decreasing fat mass while preserving lean mass. Furthermore, it significantly improved glucose metabolism and increased energy expenditure and fat utilization. Importantly, these benefits were achieved without a corresponding increase in food intake, suggesting that the treatment positively impacts energy balance.

The research also highlighted a decrease in fatty liver, demonstrated by lower levels of liver triglycerides and cholesterol. This effect was primarily attributed to the inhibition of new lipid synthesis and reduced fat accumulation. The treatment’s efficacy in enhancing metabolic processes was further evidenced by increased oxygen consumption and carbon dioxide emission, alongside elevated energy expenditure and fat oxidation.

SciSparc and Clearmind have been working together since 2022 with the aim of developing proprietary combinations of their therapies to provide safe and effective treatments for addictions and metabolic conditions. This collaboration has led to multiple patent applications, reflecting their commitment to offering enhanced therapeutic options. SciSparc, known for its cannabinoid-based pharmaceutical innovations, and Clearmind, a pioneer in psychedelic-derived therapeutics, jointly fund various studies and intellectual property related to their collaborative efforts.

SciSparc Ltd. is led by a team of experienced executives and scientists dedicated to advancing cannabinoid pharmaceuticals. The company is engaged in several drug development programs, including SCI-110 for Tourette Syndrome and Alzheimer’s disease, SCI-160 for pain management, and SCI-210 for autism and status epilepticus. SciSparc also has a subsidiary focused on selling hemp seed oil-based products on Amazon.com.

Clearmind Medicine Inc., on the other hand, is a clinical-stage biotech company specializing in the development of novel psychedelic-derived therapeutics aimed at addressing widespread and underserved health issues, such as alcohol use disorder. The company’s intellectual property portfolio consists of nineteen patent families, including 28 granted patents. Clearmind is actively seeking additional patents and remains open to acquiring new intellectual property to bolster its portfolio. Shares of Clearmind are traded on Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange under the symbol "CWY0."

This promising study underscores the potential of the combined treatment approach of SciSparc and Clearmind in addressing obesity and metabolic syndrome. By leveraging their respective expertise, both companies are well-positioned to develop innovative and effective therapeutic options for these conditions.